Want to stay updated on the latest mining news?

Stay Informed – Subscribe to latest updates. We promise to send only relevant and valuable emails, just insights you care about!

Zacks Small Cap Research – QUIT: Looking Ahead to Resubmission


By John Vandermosten, CFA

NASDAQ: QUIT

READ THE FULL QUIT RESEARCH REPORT

AchieveRx, The Quit Company (NASDAQ: QUIT) continues to make meaningful changes to the company’s image and management team. It has also presented new data at conferences and updated investors on the timeline for resubmission of the new drug application (NDA). Cash and liquid equivalents sit at just over $200 million, providing substantial flexibility to continue pre-commercialization activities and prepare the resubmission of the cytisinicline NDA.

Financial and Operational Results

Achieve’s 3Q:26 financial and operational results were detailed in a press release and Form 10-Q filing. No revenues were reported in 3Q:26. Operating expense was $20.5 million leading to a net loss of $12.1 million or $0.11 per share. The difference between operating expense and net loss is attributable to interest income and a change in warrant-related fair value. For the quarter ending September 30th, 2026 versus the same prior year period:

  • Research & development expense totaled $6.2 million, up 17% from $5.3 million, due to an increase in manufacturing and supply chain costs which were associated with manufacturing development, including purchase of raw cytisinicline inventory, finished drug product, packaging and stability expensed to R&D prior to regulatory approval. In addition, employee expenses increased and were associated with severance and increased headcount. Increases were partially offset by a decrease in clinical trial costs which were associated with the ORCA-OL trial, which was completed in October 2025;
  • General & administrative expense was $14.3 million, up 53% from $9.4 million due to an increase in stock-based compensation expense, higher employee expenses which were associated with severance, increased headcount and recruitment activity along with greater legal costs. These increases were partially offset by lower commercial launch preparation costs;
  • Net interest income was $1.5 million vs. $0.4 million as interest from higher cash balances offset interest expense;
  • Other income of $6.9 million was predominantly related to change in fair value of warrant liability, partially offset by other miscellaneous expense;
  • Net loss was $12.1 million vs. $14.4 million or $0.11 and $0.28 per share, respectively.

As of September 30th, 2026, marketable securities, cash and equivalents totaled $201.5 million. This compares to a $36.4 million balance held at the end of 2025. At the end of the third quarter, Achieve carried convertible debt of $13.0 million on the balance sheet. Cash used in operations during the first nine months of 2026 was $26.1 million versus $31.5 million in the same prior year period. Nine-month cash from financing was $190 million which includes net proceeds from the $168 million financing that was funded by a consortium of healthcare investors and the recent exercise of warrants. There are additional warrants that could raise another $150 million which will expire 20 business days following the announcement of FDA approval of cytisinicline. Following the end of the third quarter, Achieve received aggregate proceeds of $1.2 million from further warrant exercise. In August 2026, Achieve entered into an at-the-market (ATM) offering program with Jefferies to sell up to $150 million in common stock.

Chief Financial Officer Transition and Addition of Other Executives

On October 5th, 2026, Benjamin Halladay was appointed as Achieve’s Chief Financial Officer, succeeding Mark Oki, who concurrently stepped down from the role. Ben offers more than 15 years of financial management experience across commercial and launch environments. Before joining Achieve, Ben served as the Chief Financial Officer of Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue. During his tenure, Esperion deleveraged its balance sheet and acquired Corstasis Therapeutics and its product Enbumyst. He led the finance workstream through the company’s sale to ARCHIMED for up to $1.1 billion. Earlier, Ben held positions at Pfizer Inc., where he worked on Lipitor and Chantix in the Primary Care business unit, and at National Oilwell Varco, a Fortune 500 global industrial company. He holds an MBA from Fordham University and a BA from Syracuse University and is a Certified Public Accountant (inactive).

On October 7th, 2026, Achieve announced that it had appointed Kaitlyn Tuson as its Senior Vice President, Marketing and Communications. She has worked broadly across the healthcare industry supporting companies as fractional Chief Marketing Officer and will lead Achieve’s marketing, brand strategy, and corporate communications as the company prepares for the potential commercialization of cytisinicline. Kait has helped companies bring products and services to market across healthcare, including six pharmaceutical products, three of them blockbuster therapies. Previous roles include marketing and communications for Weill Cornell Medicine’s clinical services organization and with Saatchi & Saatchi Wellness where she was group director of strategy. Ms. Tuson holds a B.A. in Business, Communications and Digital Audiences from the W. P. Carey School of Business at Arizona State University.

CHEST 2026 Presentation

The company presented ORCA-OL data at the CHEST 2026 annual meeting held in Phoenix, Arizona from October 18th to 21st. The presentation highlighted the 39% quit rate for new cytisinicline users in the study. Most of the 479 enrolled adults were smokers with a minority either vaping exclusively or smoking and vaping. The population was considered hard-to-treat, where every participant had already made an attempt to quit and had tried other interventions. Participants were in their mid-fifties on average, ranging up to age 79, and many had a history of chronic conditions. Those who smoked had made an average of five quit attempts before starting the study. Quit rates, defined as four-week continuous abstinence, rose over the course of treatment, from 25.5% at weeks 9 to 12 to 31.2% at weeks 49 to 52. At the end of treatment, 39.4% of participants new to cytisinicline had quit, as had 27.8% of those who had taken cytisinicline in a prior trial and were still smoking or vaping. Cytisinicline was generally well tolerated over the 52 weeks, and the independent Data Safety Monitoring Committee (DSMC) identified no new safety signals.

Name and Ticker Change – AchieveRx, The QUIT Company

Achieve announced a name and ticker change to AchieveRx, The Quit Company (NASDAQ: QUIT) in an early November press release. The change became effective on November 10th and presents the company in the context of its mission to develop medicine for quitting smoking and vaping. Three ideas guide the company: Simplicity, Science and Second Chances, for good. CEO Andrew Goldberg references his own experiences as a physician as a reason for his drive to lead the company in this objective.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.



Source link

- Advertisement -
- Advertisement -
- Advertisement -